BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Singapore-based startup ChemT Biotechnology raises $5 M to bring AI to Biomanufacturing

June 23, 2026 | News

Total funding comprises $1 million in angel investment and a $4 million seed round



ChemT Biotechnology, an AI-driven biotechnology startup in Singapore building the intelligence layer for biomanufacturing, has closed a $4 million seed round led by Wavemaker Ventures, the early-stage fund of Wavemaker Partners, with participation from co-investment partner SEEDS, an arm of SG Growth Capital, the investment platform of EDB and Enterprise Singapore.

The round was further supported by notable investors across the United States and Asia, including Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.

Unlike conventional AI drug discovery companies or lab automation tools, ChemT builds intelligence directly into the manufacturing process itself, helping companies better understand the cells behind biomanufacturing, and provides a new way to guide cell behavior for faster, more scalable, and reliable production.

At the heart of the company is CelMo™, an AI-driven Virtual Cell platform trained on billions to trillions of proprietary biological sequencing reads and validated in the lab. CelMo™ is designed to simulate how cells respond to manufacturing conditions, genetic changes, and other stresses.

By tracking which biological processes inside a cell are being activated, suppressed, or rewired, from growth and metabolism to stress response and productivity, CelMo™ builds a dynamic picture of how cell states shift throughout manufacturing. Built on this foundation are practical applications: identifying target cell pathways to improve manufacturing performance, designing small molecules to guide cell behavior, and supporting cell engineering using AI.

ChemT's flagship small molecule product, Chemplify™, applies the same approach to T-cell manufacturing, a critical component of advanced cancer therapies. Chemplify™ has demonstrated 50% faster development, 3× scalability, 60% lower costs, and 10× higher cell expansion yield.

The financing will support the continued expansion of ChemT's AI and experimental infrastructure, advancement of its AI-designed molecular products toward GMP standards and regulatory readiness, scaling of commercial partnerships, and further development of CelMo™.

ChemT plans to expand the platform beyond CHO cells and T cells into other cellular systems, including stem cells, NK cells (Natural Killer cells, used in next-generation cancer immunotherapies), and HEK cells (Human Embryonic Kidney cells, widely used in gene therapy and biologics production), enabling broader intelligent control across biomanufacturing workflows.